LONDON |
Thu Nov 29, 2012 6:11am EST
LONDON (Reuters) – AstraZeneca has won capitulation for a new heart drug Brilinta in China, an increasingly critical marketplace for a British pharmaceuticals group.
China’s State Food and Drug Administration has released an drug import permit for a product, definition it will now be accessible for treating patients with strident coronary syndrome in a country, a association pronounced on Thursday.
Brilinta has valid improved than a cheaper general medicine clopidogrel in preventing a regularity of heart attacks, though a sales to date in markets around a universe have been disappointing.
Revitalizing a product is an early priority for new Chief Executive Pascal Soriot, who pronounced final month that Brilinta could do “far better”.
(Reporting by Ben Hirschler; Editing by Helen Massy-Beresford)
More on: Health Medicine Network